Evidence map›Paper›PMID 29990839›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2018

Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker.

M J A Walker, E S Hayes, D A Saint, G Adaikan, S Abraham, A L Goldin, G N Beatch, B A MacLeod, R A Wall, M K Pugsley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M J A WalkerDepartment of Anesthesia, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, 2176 Health Sciences Mall, Vancouver BC, V6T 1Z3, Canada. Electronic address: rsdaa@interchange.ubc.ca.
E S HayesBioCurate Pty Ltd, Parkville, VIC, Australia. Electronic address: e.hayes@biocurate.com.
D A SaintDepartment of Physiology, Faculty of Medicine, University of Adelaide, Adelaide, SA, 5005, Australia. Electronic address: david.saint@adelaide.edu.au.
G AdaikanDepartment of Obstetrics & Gynecology, Faculty of Medicine, National University of Singapore, Singapore. Electronic address: p_ganesan_adaikan@nuhs.edu.sg.
S AbrahamDepartment of Pharmacology, IIBR, Ness Ziona, Israel. Electronic address: abrahm_s@netvision.net.il.
A L GoldinDepartment of Microbiology & Molecular Genetics, University of California, Irvine, CA, United States. Electronic address: agoldin@uci.edu.
G N BeatchClinical Science, Xenon Pharmaceuticals, Burnaby, BC, Canada. Electronic address: gnbeatch@gmail.com.
B A MacLeodDepartment of Anesthesia, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, 2176 Health Sciences Mall, Vancouver BC, V6T 1Z3, Canada.
R A WallDepartment of Anesthesia, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Columbia, 2176 Health Sciences Mall, Vancouver BC, V6T 1Z3, Canada.
M K PugsleySafety Pharmacology/Toxicology Consultant, Fairfield, CT, 06825, United States. Electronic address: mkpugsley@yahoo.com.

Funding

Sodium Channel Mutations that Cause EpilepsyR01NS048336 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI GOLDIN, ALAN L · 2004 to 2013
$2.7M
NINDS NIH HHS R01 NS048336
6 · The paper itself

Abstract

backgroundRSD921, the R,R enantiomer of the kappa (k) agonist PD117,302, lacks significant activity on opioid receptors.

methodsThe pharmacological and toxicological actions were studied with reference to cardiovascular, cardiac, antiarrhythmic, toxic and local anaesthetic activity.

resultsIn rats, dogs and baboons, RSD921 dose-dependently reduced blood pressure and heart rate. In a manner consistent with sodium channel blockade it prolonged the PR and QRS intervals of the ECG. Furthermore, in rats and NHP, RSD921 increased the threshold currents for induction of extra-systoles and ventricular fibrillation (VF

conclusionsRSD921 primarily blocks sodium currents, and possesses antiarrhythmic and local anaesthetic activity.

Indexed as

Action PotentialsAdministration, IntravenousAnesthetics, LocalAnimalsAnti-Arrhythmia AgentsAntihypertensive AgentsArrhythmias, CardiacBlood PressureDisease Models, AnimalDogsDose-Response Relationship, DrugFemaleGuinea PigsHeart RateHumansInjections, IntradermalAnesthetics, LocalAnti-Arrhythmia AgentsAntihypertensive AgentsPD 117302PyrrolesSodium Channel BlockersSodium ChannelsThiophenesAntiarrhythmicElectrophysiologyLangendorffLocal anestheticMyocyteNeuromuscularPharmacokineticsRSD921Sodium and potassium blockerToxicology

Identifiers

PMID29990839
PMCPMC6492542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.